- Home
- OKYO
OKYO
OKYO Pharma Limited
as 11-14-2024 3:35pm EST
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
| Founded: | 2007 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 38.2M | IPO Year: | 2022 |
| Target Price: | $7.00 | AVG Volume (30 days): | 128.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.81 - $2.12 | Next Earning Date: | 11-22-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest OKYO Pharma Limited News
OKYO Breaking Stock News: Dive into OKYO Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
GlobeNewswire
23 days ago
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
TipRanks
a month ago
OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug
GlobeNewswire
a month ago
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
GlobeNewswire
2 months ago
OKYO Pharma Announces Chairman Acquires Shares
GlobeNewswire
2 months ago
OKYO Pharma Announces Chairman Acquires Shares
GlobeNewswire
3 months ago
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
ACCESSWIRE
3 months ago
OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Compare OKYO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OKYO OKYO Pharma Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.